vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and First Bancorp, Inc (FNLC). Click either name above to swap in a different company.
First Bancorp, Inc is the larger business by last-quarter revenue ($25.8M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). First Bancorp, Inc runs the higher net margin — 39.4% vs -0.8%, a 40.2% gap on every dollar of revenue. On growth, First Bancorp, Inc posted the faster year-over-year revenue change (17.5% vs -25.7%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $-15.8M). Over the past eight quarters, First Bancorp, Inc's revenue compounded faster (18.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
CTMX vs FNLC — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $25.8M |
| Net Profit | $-154.0K | $10.2M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 48.1% |
| Net Margin | -0.8% | 39.4% |
| Revenue YoY | -25.7% | 17.5% |
| Net Profit YoY | 97.6% | 39.7% |
| EPS (diluted) | — | $0.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $25.8M | ||
| Q3 25 | — | $24.5M | ||
| Q2 25 | $18.7M | $22.5M | ||
| Q1 25 | $50.9M | $21.8M | ||
| Q4 24 | $38.1M | $22.0M | ||
| Q3 24 | $33.4M | $20.5M | ||
| Q2 24 | $25.1M | $19.2M | ||
| Q1 24 | $41.5M | $18.5M |
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $9.1M | ||
| Q2 25 | $-154.0K | $8.1M | ||
| Q1 25 | $23.5M | $7.1M | ||
| Q4 24 | $18.9M | $7.3M | ||
| Q3 24 | $5.7M | $7.6M | ||
| Q2 24 | $-6.5M | $6.2M | ||
| Q1 24 | $13.8M | $6.0M |
| Q4 25 | — | 48.1% | ||
| Q3 25 | — | 45.2% | ||
| Q2 25 | -6.9% | 43.7% | ||
| Q1 25 | 44.4% | 39.3% | ||
| Q4 24 | 46.4% | 39.5% | ||
| Q3 24 | 12.3% | 44.6% | ||
| Q2 24 | -33.7% | 38.8% | ||
| Q1 24 | 28.1% | 39.3% |
| Q4 25 | — | 39.4% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | -0.8% | 35.8% | ||
| Q1 25 | 46.2% | 32.5% | ||
| Q4 24 | 49.6% | 33.1% | ||
| Q3 24 | 17.2% | 36.9% | ||
| Q2 24 | -26.0% | 32.1% | ||
| Q1 24 | 33.3% | 32.5% |
| Q4 25 | — | $0.91 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.72 | ||
| Q1 25 | — | $0.63 | ||
| Q4 24 | — | $0.66 | ||
| Q3 24 | — | $0.68 | ||
| Q2 24 | — | $0.55 | ||
| Q1 24 | — | $0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | $95.5M |
| Stockholders' EquityBook value | $119.9M | $283.1M |
| Total Assets | $175.1M | $3.2B |
| Debt / EquityLower = less leverage | — | 0.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $95.5M | ||
| Q3 25 | — | $95.5M | ||
| Q2 25 | — | $95.0M | ||
| Q1 25 | — | $70.0M | ||
| Q4 24 | — | $95.0M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $70.0M | ||
| Q1 24 | — | $70.0M |
| Q4 25 | — | $283.1M | ||
| Q3 25 | — | $274.6M | ||
| Q2 25 | $119.9M | $265.5M | ||
| Q1 25 | $25.0M | $259.7M | ||
| Q4 24 | $-456.0K | $252.5M | ||
| Q3 24 | $-23.5M | $256.8M | ||
| Q2 24 | $-31.2M | $244.7M | ||
| Q1 24 | $-31.7M | $242.6M |
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $175.1M | $3.2B | ||
| Q1 25 | $98.5M | $3.2B | ||
| Q4 24 | $120.5M | $3.2B | ||
| Q3 24 | $139.0M | $3.1B | ||
| Q2 24 | $159.2M | $3.1B | ||
| Q1 24 | $184.7M | $3.0B |
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $37.8M |
| Free Cash FlowOCF − Capex | $-15.8M | $34.6M |
| FCF MarginFCF / Revenue | -84.6% | 133.9% |
| Capex IntensityCapex / Revenue | 0.1% | 12.5% |
| Cash ConversionOCF / Net Profit | — | 3.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $55.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $37.8M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | $-15.8M | $7.4M | ||
| Q1 25 | $-21.0M | $2.2M | ||
| Q4 24 | $-19.9M | $26.0M | ||
| Q3 24 | $-20.7M | $9.8M | ||
| Q2 24 | $-19.5M | $6.4M | ||
| Q1 24 | $-26.0M | $-1.5M |
| Q4 25 | — | $34.6M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | $-15.8M | $7.2M | ||
| Q1 25 | $-21.2M | $828.0K | ||
| Q4 24 | $-20.0M | $24.6M | ||
| Q3 24 | $-20.7M | $9.6M | ||
| Q2 24 | $-19.6M | $6.3M | ||
| Q1 24 | $-26.2M | $-1.8M |
| Q4 25 | — | 133.9% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | -84.6% | 32.1% | ||
| Q1 25 | -41.6% | 3.8% | ||
| Q4 24 | -52.5% | 111.7% | ||
| Q3 24 | -62.1% | 47.0% | ||
| Q2 24 | -78.2% | 32.9% | ||
| Q1 24 | -63.1% | -9.8% |
| Q4 25 | — | 12.5% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 0.1% | 0.6% | ||
| Q1 25 | 0.2% | 6.2% | ||
| Q4 24 | 0.2% | 6.7% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 0.3% | 1.8% |
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | -0.89× | 0.31× | ||
| Q4 24 | -1.05× | 3.58× | ||
| Q3 24 | -3.61× | 1.29× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | -1.89× | -0.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FNLC
Segment breakdown not available.
